News
RNA
24.36
+2.22%
0.53
Artisan International Small-Mid Fund Q1 2024 Earnings Preview
Artisan Partners is an independent investment management firm. Global equities advanced in Q1 primarily on investor expectations of central bank interest rate cuts in the US, EU and UK. The portfolio outperformed the MSCI ACWI ex US SMID Index. The global energy transition is a growing portfolio theme.
Seeking Alpha · 3d ago
Edgewise gets EU orphan drug status for muscular dystrophy drug
Edgewise gets EU orphan drug status for muscular dystrophy drug. Edgewise Therapeutics has received orphan drug designation from EU regulators for its drug candidate sevasemten. The drug candidate is in the treatment of Becker muscular dy Strophy and Duchenne muscular dystrophy.
Seeking Alpha · 5d ago
AVIDITY BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 6d ago
Weekly Report: what happened at RNA last week (0415-0419)?
Weekly Report · 6d ago
FYBR, BCRX and SABR are among after hour movers
Seeking Alpha · 04/18 20:56
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
Cathie Wood's fund ARK Invest invests in companies she expects to be the leaders of disruptive innovation. The fund is down 15% this year. Wood is a fan of investing in the companies of tomorrow. Her fund invests in the cutting-edge technologies of the day.
Benzinga · 04/18 18:29
Weekly Report: what happened at RNA last week (0408-0412)?
Weekly Report · 04/15 10:42
Where Avidity Biosciences Stands With Analysts
Avidity Biosciences (NASDAQ:RNA) has an average price target of $36.83. The company's 12-month price targets reflect a 60.13% increase from the previous average of $23.00. 6 analysts have shared their insights on Avidity B biosciences in the last three months. Avidity bioscience is a biotechnology company developing novel therapies to treat rare diseases. The analysts have an average rating of 'buy'
Benzinga · 04/11 12:00
Avidity Biosciences Price Target Maintained With a $35.00/Share by Needham
Dow Jones · 04/11 11:34
Needham Reiterates Buy on Avidity Biosciences, Maintains $35 Price Target
Benzinga · 04/11 11:23
Analysts Offer Insights on Healthcare Companies: Carisma Therapeutics (CARM), Avidity Biosciences (RNA) and Vera Therapeutics (VERA)
TipRanks · 04/11 10:40
RNA January 2025 Options Begin Trading
NASDAQ · 04/08 15:29
Weekly Report: what happened at RNA last week (0401-0405)?
Weekly Report · 04/08 10:46
Guru Fundamental Report for RNA
NASDAQ · 04/04 20:15
Avidity Biosciences Filed Prospectus For Proposed Resale Or Other Disposition By Selling Securityholders Of Up To 15.2M Shares Of Common Stock; Prospectus For Up To 9M Shares Issuable Upon Exercise Of Pre-funded Warrants
Benzinga · 04/02 20:24
Avidity Biosciences files to sell 24.26M common shares for holders
Healthcare Avidity Biosciences files to sell 24.26M common shares for holders Apr. 02, 2024 4:24 PM ETAvidity B biosciences, Inc. (RNA) Stock Avidity has filed a prospectus related to the proposed resale of 24. 26M commonShares by selling stockholders.
Seeking Alpha · 04/02 20:24
AVIDITY BIOSCIENCES - FILES PROSPECTUS FOR PROPOSED RESALE OR OTHER DISPOSITION BY SELLING SECURITYHOLDERS OF UP TO 15.2 MLN SHARES OF COMMON STOCK
Reuters · 04/02 20:19
AVIDITY BIOSCIENCES:PROSPECTUS FOR UP TO 9 MLN SHARES ISSUABLE UPON EXERCISE OF PRE-FUNDED WARRANTS TO ACQUIRE COMMON SHARES BY SELLING SECURITYHOLDERS
Reuters · 04/02 20:19
Weekly Report: what happened at RNA last week (0325-0329)?
Weekly Report · 04/01 10:44
AVIDITY BIOSCIENCES INC <RNA.O>: EVERCORE ISI RAISES TARGET PRICE TO $40 FROM $28
Reuters · 04/01 05:53
More
Webull provides a variety of real-time RNA stock news. You can receive the latest news about Avidity Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RNA
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.